治疗药物满意度问卷（SATMED-Q）的最小重要差异。
Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q).
机构信息
Health Outcomes Research Department, Corporate Affairs and Market Access Unit, Pfizer España, Alcobendas, Madrid, Spain.
出版信息
BMC Med Res Methodol. 2011 Oct 20;11:142. doi: 10.1186/1471-2288-11-142.
BACKGROUND
A previous study has documented the reliability and validity of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) in exploring patient satisfaction with medicines for chronic health conditions in routine medical practice, but the minimally important difference (MID) of this tool is as yet unknown. The objective of this research was to estimate the MID for the SATMED-Q total score and six constituent domains.
METHODS
The sample of patients (456 subjects, mean age 59 years, 53% male) used for testing psychometric properties was also used to assess MID. Item #14 of the Treatment Satisfaction Questionnaire for Medication (TSQM) was used as an anchor reference since it directly explores satisfaction with medicine on a 7-point ordinal scale (from extremely satisfied to extremely dissatisfied, with a neutral category). Patients were classified into four categories according to responses to this item (extremely satisfied/dissatisfied, very satisfied/dissatisfied, satisfied/dissatisfied, neither satisfied nor dissatisfied (neutral), and calculations were made for the total score and each domain of the SATMED-Q using standardised scores. The mean absolute differences in total score (and domains) between the neutral category and the satisfied/dissatisfied category were considered to be the MID. Effect sizes (ES) were also computed.
RESULTS
The MID for the total score was 13.4 (ES = 0.91), while the domain values ranged from 10.3 (medical care domain, ES = 0.43) to 20.6 (impact on daily living, ES = 0.85). Mean differences in satisfaction (as measured by the total SATMED-Q score and domain scores) using the levels of satisfaction established by item #14 were significantly different, with F values ranging from 12.2 to 88.8 (p < 0.001 in all cases).
CONCLUSION
The SATMED-Q was demonstrated to be responsive to different levels of patient satisfaction with therapy in chronically ill subjects. The MID obtained was 13.4 points for the overall normalised scoring scale, and between 10.3 and 20.6 points for domains.
背景
先前的研究已经证明了治疗药物满意度问卷（SATMED-Q）在探索慢性健康状况患者对药物治疗满意度方面的可靠性和有效性，但是该工具的最小临床重要差异（MID）尚不清楚。本研究旨在评估 SATMED-Q 总分和六个组成部分的 MID。
方法
用于测试心理测量特性的患者样本（456 例患者，平均年龄 59 岁，53%为男性）也用于评估 MID。治疗药物满意度问卷（TSQM）的第 14 项被用作锚定参考，因为它直接在 7 点有序量表（从非常满意到非常不满意，包括中性类别）上探索对药物的满意度。根据该项目的回答，患者被分为四类（非常满意/不满意、非常满意/不满意、满意/不满意、既不满意也不满意（中性），并对 SATMED-Q 的总分和各个域使用标准化分数进行计算。中性类别和满意/不满意类别之间的总分（和域）的平均绝对差异被认为是 MID。还计算了效应大小（ES）。
结果
总分的 MID 为 13.4（ES=0.91），而各域值范围为 10.3（医疗保健域，ES=0.43）至 20.6（对日常生活的影响，ES=0.85）。使用第 14 项确定的满意度水平测量的满意度（如总 SATMED-Q 评分和域评分所示）的平均差异具有统计学意义，F 值范围从 12.2 到 88.8（所有情况下均 p<0.001）。
结论
SATMED-Q 被证明能够响应慢性疾病患者对治疗的不同满意度水平。获得的 MID 为 13.4 分，用于整体标准化评分量表，以及 10.3 到 20.6 分用于各域。
Zotero 插件